Q-omics provides the consensus-scored GNL2P1 profile across patient tissues and cancer cell-line models. GNL2P1 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, GNL2P1 is differentially expressed in 5, with the highest sampling consensus in THCA. Additionally, GNL2P1 RNA expression shows 7,062 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight BLCA, THCA, and KIRP as cancer lineages where GNL2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GNL2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GNL2P1 survival associations across molecular data types. GNL2P1 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GNL2P1 RNA expression–survival associations across cancer types. High GNL2P1 expression shows unfavorable associations in MESO, LUAD and STAD, but favorable associations in BLCA, CHOL and LGG. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .008). Together, the overview and detailed table identify BLCA as the clearest survival context for GNL2P1 RNA expression.
This table summarizes GNL2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for GNL2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GNL2P1 shows lower tumor expression in THCA, KIRC, BRCA, UCEC and KIRP. The THCA box plot shows higher GNL2P1 RNA expression in normal versus tumor tissue (log2 FC = −0.072, t-test p < 0.001).
This table shows molecular features associated with GNL2P1 in patient tissues and cancer cell lines. In patient samples, GNL2P1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
